U.S. Stock Market Midday Update

Inotiv fell 23.14%, with increased trading volume. Based on recent key news:

1. On June 3, Inotiv announced it had entered into a restructuring support agreement and filed for voluntary prepackaged bankruptcy. The company plans to reduce approximately $326 million in debt through a quick restructuring and secure $65 million in new financing, including $25 million in debtor-in-possession financing. This news led to a significant drop in stock price.

2. On June 3, Inotiv expected to seek confirmation of its restructuring plan and expedite the bankruptcy process. The company stated that these measures would strengthen its financial foundation and support future growth; however, the market reacted negatively to the bankruptcy news, and the stock price continued to decline.

3. On June 1, the technical outlook remained bearish, with the stock price below major moving averages. Although the company mentioned operational improvements in DSA during its earnings call, it failed to fully offset negative sentiment, leading to pressure on the stock price. The market reacted negatively to the bankruptcy news, putting pressure on the stock price.

Top Stocks by Trading Volume in the Industry

Danaher rose 4.42%, with active trading. Based on recent key news:

1. On June 4, Danaher's subsidiary Mammotome received CE certification, allowing its HydroMARK™ Plus marker to be distributed in the European market. This development marks an important milestone in the company's product expansion, driving the stock price up.

2. On June 2, SCIEX launched a new system, novus V55, equipped with the latest software and AI tools to enhance functionality. This innovative move boosted market confidence in Danaher's technological strength, propelling the stock price higher.

3. On June 1, SCIEX announced a comprehensive expansion of its ZenoTOF product line, including enhancements in software, integration, and key collaborations. This news further solidified Danaher's leading position in the biopharmaceutical field, boosting investor confidence. The medical device industry is seeing active innovation, enhancing market confidence.

Thermo Fisher Scientific rose 2.40%. Based on recent key news:

1. On June 1, GuruFocus released an analysis stating that the intrinsic value per share of Thermo Fisher Scientific is approximately $477.60, combined with the current stock price of $492.51, indicating reasonable valuation. The company's first-quarter performance exceeded expectations, with revenue reaching $11.01 billion and adjusted earnings per share of $5.44. Additionally, the company signed an agreement to sell its microbiology business for approximately $1.075 billion. Valuation differences among multiple models and complex corporate dynamics suggest the stock is in a delicate position.

2. On June 4, Zhongyou Securities released a research report stating that the overall CXO industry overseas is showing a differentiated recovery pattern, with a substantial improvement in the global biopharmaceutical financing environment, gradually driving demand recovery. Thermo Fisher Scientific has demonstrated strong performance resilience, with the acquisition of Clario beginning to contribute to performance, and the company significantly raised its full-year revenue guidance On June 1, Thermo Fisher Scientific showcased the latest advancements in mass spectrometry technology at the American Society for Mass Spectrometry conference, launching a new Orbitrap mass spectrometry platform, AI-enhanced software, and streamlined workflows aimed at helping scientists achieve accurate and timely results. The global biopharmaceutical financing environment is improving, with demand rebounding.

Tempus AI rose 11.03%. Based on recent key news:

1. On June 3, Tempus AI partnered with Yale New Haven Hospital and Memorial Sloan Kettering Cancer Center to establish a digital pathology IMS open-source alliance. This initiative aims to accelerate the democratization and standardization of digital pathology, enhancing the company's influence in the precision medicine field and driving up stock prices.

2. On June 2, a FactSet survey revealed that analysts lowered Tempus AI's 2026 EPS estimate to -$0.37, with a target price of $64. Despite the downward revision in earnings expectations, the market remains optimistic about the company's future growth, supporting the rise in stock prices.

3. On June 1, Tempus AI director David R. Epstein sold 250 shares of common stock at a transaction price of $49.4 per share. Although there was insider selling, market confidence in the company's prospects was not significantly affected. The AI industry is experiencing strong growth, with increasing market demand for innovative technologies.

Stocks ranked among the top in industry market capitalization

Agilent Technologies rose 2.11%. Based on recent key news:

1. On June 3, Agilent Technologies announced a collaboration with OpenAI and Boston Consulting Group to accelerate AI-driven scientific innovation. This partnership aims to strengthen the company's capabilities in AI technology, driving up stock prices.

2. On June 2, Agilent received FDA approval to expand the use of the PD-L1 IHC 22C3 pharmDx test to cover multiple cancer types. This approval broadens market applications, enhances investor confidence, and drives up stock prices.

3. On June 1, Agilent announced the acquisition of Biocare for $950 million, with plans to complete integration by fiscal year 2026. This move aims to expand clinical and research product lines, enhance market competitiveness, and boost stock prices. AI collaborations and FDA approvals are increasing market confidence